Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Nov
09
Today In Oncology
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Two Forever Chemicals Associated Higher Risk of ER-Negative Breast Cancer
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Extended Follow-up of Nivolumab Ipilimumab for Localized dMMR MSI-H Gastric GEJ Cancer
Claudia Henschke, PhD, MD Finding Lung Cancer in Time
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo